WO2003029282A3 - Tumor-peptidantigene aus humanem prdi-bf1-protein - Google Patents

Tumor-peptidantigene aus humanem prdi-bf1-protein Download PDF

Info

Publication number
WO2003029282A3
WO2003029282A3 PCT/EP2002/010701 EP0210701W WO03029282A3 WO 2003029282 A3 WO2003029282 A3 WO 2003029282A3 EP 0210701 W EP0210701 W EP 0210701W WO 03029282 A3 WO03029282 A3 WO 03029282A3
Authority
WO
WIPO (PCT)
Prior art keywords
tumor
ctl
human
prdi
protein
Prior art date
Application number
PCT/EP2002/010701
Other languages
English (en)
French (fr)
Other versions
WO2003029282A2 (de
Inventor
Matthias Theobald
Carina Lotz
Original Assignee
Immugenics Ag
Matthias Theobald
Carina Lotz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immugenics Ag, Matthias Theobald, Carina Lotz filed Critical Immugenics Ag
Priority to AU2002362494A priority Critical patent/AU2002362494A1/en
Publication of WO2003029282A2 publication Critical patent/WO2003029282A2/de
Publication of WO2003029282A3 publication Critical patent/WO2003029282A3/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Die Erfindung betrifft tumorassoziierte Oligopeptide, die von CD8-positiven zytotoxischen T-Lymphozyten (ZTL) aIs Peptidantigen erkannt werden, und die eine ZTL-induzierte Lyse und/oder Apoptose von Tumorzellen, insbesondere Zellen des Multiplen Myeloms herbeiführen. Die Oligopeptide weisen Arninosäuresequenzen auf, die Teilsequenzen des humanen PRDI-BF1-Proteins entsprechen. Jedes Oligopeptid stellt ein Epitop für CD8-positive ZTL dar und ist dazu geeignet, eine auf humanes Leukozyten-Antigen der Molekülgruppe 'MHC Klasse I', Allelvariante A2 (kurz: A2) eingeschränkte (restringierte) Immunantwort von CD8-positiven ZTL gegen Multiple- Myelom-Zellen und andere Tumorzellen zu induzieren.
PCT/EP2002/010701 2001-09-29 2002-09-24 Tumor-peptidantigene aus humanem prdi-bf1-protein WO2003029282A2 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002362494A AU2002362494A1 (en) 2001-09-29 2002-09-24 Tumor-peptide antigens from the human prdi-bf1-protein

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10148236.1 2001-09-29
DE10148236A DE10148236A1 (de) 2001-09-29 2001-09-29 Tumor-Peptidantigene aus humanem PRDI-BF1-Protein

Publications (2)

Publication Number Publication Date
WO2003029282A2 WO2003029282A2 (de) 2003-04-10
WO2003029282A3 true WO2003029282A3 (de) 2004-04-01

Family

ID=7700869

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/010701 WO2003029282A2 (de) 2001-09-29 2002-09-24 Tumor-peptidantigene aus humanem prdi-bf1-protein

Country Status (3)

Country Link
AU (1) AU2002362494A1 (de)
DE (1) DE10148236A1 (de)
WO (1) WO2003029282A2 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8075895B2 (en) * 2009-09-22 2011-12-13 Janssen Pharmaceutica N.V. Identification of antigenic peptides from multiple myeloma cells

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996006168A2 (en) * 1994-08-18 1996-02-29 La Jolla Cancer Research Foundation Retinoblastoma protein-interacting zinc finger proteins

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996006168A2 (en) * 1994-08-18 1996-02-29 La Jolla Cancer Research Foundation Retinoblastoma protein-interacting zinc finger proteins
US6069231A (en) * 1994-08-18 2000-05-30 La Jolla Cancer Research Foundation PR domain peptides

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHADWICK RB ET AL.: "Candidate tumor suppressor RIZ is frequently involved in colorectal carcinogenesis", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCE USA, vol. 97, no. 6, 14 March 2000 (2000-03-14), pages 2662 - 2667, XP002248095 *
GHOSH N ET AL.: "Positive Regulatory Domain I Binding Factor 1 Silences Class II Transactivator Expression in Multiple Myeloma Cells", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 276, no. 18, 4 May 2001 (2001-05-04), pages 15264 - 15268, XP002248094 *

Also Published As

Publication number Publication date
AU2002362494A1 (en) 2003-04-14
DE10148236A1 (de) 2003-04-24
WO2003029282A2 (de) 2003-04-10

Similar Documents

Publication Publication Date Title
WO2006046239A3 (en) A thymus-specific protein
WO2002064057A3 (en) Use of cell penetrating peptides to generate antitumor immunity
WO2000020445A3 (en) Tumor antigens and ctl clones isolated by a novel procedure
US10172925B2 (en) Uses of partial peptides of survivin and variations thereof
WO2003011331A3 (en) Materials and methods relating to improved vaccination strategies
WO2003029282A3 (de) Tumor-peptidantigene aus humanem prdi-bf1-protein
CN101698852B (zh) 具有cd137l功能的蛋白或多肽及其基因和应用
WO2002072627A3 (en) Induction of anti-tumor cytotoxic t-lymphocytes in humans using peptide epitopes found by computer based algorithms for vaccination
AU2003239659A1 (en) Peptide epitopes common to antigens of the same multigene family
NZ591133A (en) Novel melanoma antigen peptide and uses thereof
ATE308559T1 (de) PEPTIDE, DIE CEA (ßCARCINOEMBRYONIC ANTIGENß) BINDEN
WO2003063759A3 (en) Hsp peptides and analogs for modulation of immune responses via antigen presenting cells
WO2012015979A3 (en) Hmgb1-derived peptides enhance immune response to antigens
WO2003091383A3 (fr) Epitopes t de l'antigene epha2.
UA83989C2 (ru) Выделенный пептид, который стимулирует противоопухолевый иммунный ответ, фармацевтическая композиция на его основе и ее применение
CO5280140A1 (es) Antigeno (c42) asociado a tumores
AU2003264535A1 (en) Tumor antigen protein and utilization thereof
WO2009083968A8 (en) Novel protein
WO2002069691A3 (en) Immunogenic hiv peptides for use as reagents and vaccines
WO2003037917A1 (fr) Antigene de tumeur
WO2004056316A8 (en) Vaccines against hiv-1 tat protein to generate neutralizing antibodies
CA2152075A1 (en) Vaccination with peptide of mhc class ii molecules for treatment of autoimmune disease
WO2006078268A3 (en) A peptide that elicits neutralizing antibodies targeting the hiv co-receptor, ccr5
EP0974653A3 (de) Menschliches Gen und Protein eines Magenkrebs-Antigens
FR2856598A1 (fr) Peptides derives de la proteine mmp-2 et leur utilisation en immunotherapie antitumorale

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: FESTSTELLUNG EINES RECHTSVERLUSTS NACH REGEL 69(1) EPUE FORM 1205A VON 17-08-2004

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP